Interview with Safia Rizvi, Managing Director, UCB India
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
Address: 504, Peninsula TowersPeninsula Corporate ParkGanpatrao Kadam Marg, Lower ParelIND – Mumbai 400 013,India
Tel: +91 22 40 49 11 11
Web: http://www.ucb.com/india/
At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients’ needs.
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry.
We combine biology and chemistry to make major breakthroughs.
By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
We partner with the leaders in the pharmaceutical industry.
The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners – we play to our strengths and tap into the organisations with greater or complementary strengths.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Vimpat® (lacosamide)
Epilepsy
Keppra® (levetiracetam)
Epilepsy
Neupro® (rotigotine)
Parkinson’s disease
Restless Legs Syndrome
Nootropil® (piracetam)
Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII)
Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol)
Crohn’s disease
Rheumatoid arthritis
Xyzal® (levocetirizine)
Allergies
Zyrtec® (cetirizine)
Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII)
Respiratory disease
You have only recently been appointed Managing Director for the first time in your career. How did your first year with UCB India go so far? My first year at…
“From illness to wellness” – this is what Apollo Life is all about. Ariz Rizvi, president of Apollo Life, gives his insight into the current state of occupational and rehabilitative…
Sridhar Ranganathan, managing director of Allergan, explains how the affiliate revolutionized the ophthalmologic market in India and how it engages with the different stakeholders, ranging from government institutions to the…
Indian pharma production is growing rapidly – boosted by the Modi government’s ‘Make in India’ campaign – and both Indian companies and multinationals implanted in the world’s second most populous…
A strong advocate for women’s health and the first managing director of Roche Diagnostics India to be under 40 years old, Dr. Shravan Subramanyam shares his insights on the Indian…
With his over 25 years’ experience in running growing businesses and establishing start-ups, Ranjit Madan, CEO of the Life Sciences Sector Skill Development Council (LSSSDC), explains the journey of the…
Dilip G Shah, secretary-general of the Indian Pharmaceutical Alliance (IPA) and member of the Expert Review Committee on Access to Medicine (ATM), discusses the association’s commitment to assisting the Indian…
A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the productive investments that the company has made in India, and his intention to make digital…
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the leading country in its region. Despite the prevalence…
As a young pathbreaking transformer in the Indian pharmaceutical landscape, Yogesh Agrawal, managing director of Ajanta Pharma Ltd., shares his desire to accelerate the company’s expansion in the US. Out…
Sanjay Bhutani, managing director of Bausch & Lomb India and SAARC operations, gives his insights into the thriving visual care industry which has allowed the company to launch 31 intraocular…
At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based pharmaceutical companies in India, putting the patient at the center of all that they do is…
Bhupendra Singh, chairman of the Indian National Pharmaceutical Pricing Authority (NPPA), provides an overview of the current mechanisms governing the pharmaceutical and life sciences industry in India, highlighting the challenges…
See our Cookie Privacy Policy Here
